// App-Quantinova.ai

4029 : A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Researchers

Presenter

  • P. Leif Bergsagel

Principal Investigators

  • Seema Singhal

  • William Ho

  • Keith Stewart

  • Ruben Niesvizky

  • Raymond L. Comenzo

  • William I. Bensinger

  • Daniel Lebovic

  • Younjeong Choi

  • Dan Lu

  • Dorothy French

  • Elicia Penuel

Medical Centers

  • Mayo Clinic, Scottsdale, AZ

  • Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Bladder Cancer

  • Multiple Myeloma

  • Hypercalcaemia

  • Neutropenia

  • Angina

  • Solid malignancies

  • Anemia

Biomarkers

  • Creatinine

Drug/Treatment

  • MFGR1877S

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved